News | News By Subject | News by Disease News By Date | Search News

Crohn's disease News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Why Celgene (CELG) Gets No R-E-S-P-E-C-T, But Should     6/14/2017
Gilead (GILD) Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report     11/2/2016
What You May Have Missed: Critics Point to Problems With Celgene (CELG)’s Crohn’s Drug Trial Design     10/20/2016
TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda (TKPYY)     7/6/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015     3/24/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs     3/8/2016
Galapagos (GLPG.BR) Crohn’s Trial Data Might Make it An Attractive M&A Target for Amgen (AMGN)     12/9/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
TiGenix's Cx601 Meets Primary Endpoint in Phase III Study     8/31/2015
AstraZeneca PLC (AZN) Offloads Crohn's Disease Drug for $215 Million     7/10/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
J.P. Morgan: Celgene (CELG) to Fast-Track Crohn's Drug, Provides Estimates Up to 2020     1/13/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Celgene (CELG)’s New Crohn’s Disease Drug Impressing Analysts     10/21/2014

News from Around the Web
Mothers Can Pass Traits To Offspring Through Bacteria's DNA, Washington University in St. Louis Study     2/23/2015
Could Gut Bacteria That Help Us Digest Beer & Bread Fight Disease, Too? University of Michigan Medical School Study     1/8/2015
Genetically Engineered Bacteria Could Help in Crohn's and Colitis, Centre de Physiopathologie de Toulouse-Purpan Study     11/2/2012
Potential New Drug Therapy for Crohn's Disease, University of California, San Diego (UCSD) Study     10/18/2012
Discovery Finds Cancer Drugs Offer New Hope for Crohn's Disease and Sarcoidosis, Case Western Reserve University Study     12/1/2010
Adding Immunomodulating Agents and Corticosteroids to Adalimumab Increases Risks of Infection for Patients With Crohn's Disease, Mayo Clinic Study Presented at American College of Gastroenterology     10/22/2010
American College of Gastroenterology: Acute IBD Flares Respond to Infliximab, University of Pittsburgh Study     10/20/2010
American College of Gastroenterology: Upfront Biologics Improve Crohn's Outcomes, State University of New York at Buffalo Study     10/19/2010
Broccoli, Plantains May Stop Crohn's Disease Relapse, University of Liverpool and Collaborators Study     8/26/2010
Prebiotics Won't Relieve Crohn's, According to Research Presented at Digestive Disease Week     5/7/2010
Better Treatment Found for Crohn's Disease, Mayo Clinic Study     4/15/2010
Genetic Variants Associated With a Risk of Crohn's Disease, University of Copenhagen Study     4/7/2010
Gene Discovery Gives Clues to Crohn's Disease, Colitis, University College London Study     11/5/2009
UK Scientists Say They've Found A Cure For Crohn's, University of Nottingham Study     6/26/2009
Probiotic May Help Treat Crohn's Disease, Institut National de Recherche Agronomique Study     10/21/2008

Press Releases
RedHill Biopharma (RDHL) Announces Unanimous Positive DSMB Recommendation For Continuation Of The Phase III Study With RHB-104 For Crohn’s Disease     7/31/2017
Merck & Co. (MRK) Announces U.S. Launch Of RENFLEXIS (Infliximab-Abda), A Biosimilar Of Remicade, For All Eligible Indications     7/24/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease     7/12/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease     7/12/2017
Takeda (TKPYY) And TiGenix Announce That Swissmedic Has Accepted For Review The File On Cx601 For The Treatment Of Complex Perianal Fistulas In Crohn's Disease Patients     6/20/2017
TiGenix Partners With U.S. And European Patient Advocacy Groups Focused On Crohn’s Disease And Ulcerative Colitis     6/15/2017
Atlantic Healthcare Develops Tablet Formulations Of Alicaforsen To Treat Crohn's Disease And Ulcerative Colitis     5/30/2017
AbbVie (ABBV) Announces Positive Phase II Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease     5/9/2017
Takeda (TKPYY) Release: New Real-World Analyses Support Effectiveness And Safety Of Entyvio (Vedolizumab) For Ulcerative Colitis And Crohn's Disease     5/8/2017
Galapagos (GLPG.BR) Presents Three Posters On Filgotinib In Crohn's Disease At DDW 2017     5/8/2017
High Response And Remission Rates In Anti-Tnfa Naïve Patients Treated With Qu Biologics’ Novel Immune Therapy For Crohn’s Disease     4/20/2017
RedHill Biopharma (RDHL) Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn’s Disease     3/21/2017
Galapagos (GLPG.BR) Release: New Phase II Studies With Filgotinib In Small Bowel And Fistulizing Crohn's Disease     3/10/2017
TiGenix Announces Positive Topline Week-104 Data For Cx601 ADMIRE-CD Trial     3/9/2017
Crohn's and Colitis Foundation of America RISK Stratification Study Reveals Potential New Approach To Precision Medicine For Pediatric Patients     3/2/2017